disease progression

Nerve impulses travel in a “dual cable” with myelin, playing additional roles to what was previously thought, new research has found. This discovery advances human knowledge of how brain connections work, and may help scientists understand more accurately what happens when myelin is lost — which is what occurs…

Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterward considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests. Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS…

Despite the fact that being obese or overweight may worsen multiple sclerosis (MS) prognosis, people with the neurodegenerative disease are not more likely to adopt weight loss diets, a small study suggests. The study, “Obesity, dieting, and multiple sclerosis,” was published in the journal Multiple Sclerosis and Related…

A common mutation in the fat-mass obesity (FTO) gene is associated with obesity and increased disability in people with multiple sclerosis (MS), according to a Kuwaiti study. The data, which showed no link between this mutation and an increased risk of MS, highlights the need for more studies about…

Regeneration in the brain is reduced in people with primary progressive multiple sclerosis (PPMS), but enhanced during disease activity in those with relapsing-remitting MS (RRMS), a study reports. The results also show that regeneration is unaffected by treatment with disease-modifying therapies (DMTs), as shown by the levels…

The Government of Alberta is investing CA$1 million into a research project that will follow for years a group of people with multiple sclerosis — with varying disease types and at differing stages — to better understand progression in MS. The province’s contribution brings to more than CA$10 million (about…

Processes related to metabolism in brain cells known as astrocytes may be at the origin of multiple sclerosis (MS), particularly underlying the inflammation and damage to the nervous system seen in progressive disease, a study in mice found.

Stopping the migration of immune B-cells through the blood-brain barrier by blocking ALCAM, a molecule linked to the progression of multiple sclerosis (MS), lessened disease severity in an MS mouse model, a new study shows. Details of the discovery were reported…

A large retrospective study suggests that a magnetic resonance imaging (MRI) marker — called “brain atrophied T2 lesion volume” — could help predict the timing of multiple sclerosis (MS) progression. According to the study, this marker was the only MRI parameter capable of predicting disease progression, compared with other…

A 30-year study of outcomes in multiple sclerosis (MS) patients reports that radiological findings in the first year of disease onset, and the amount of disability evident at five years, helps to predict both the likelihood of a person advancing to secondary progressive MS (SPMS) and long-term survival. The study,…

People with relapsing-remitting multiple sclerosis (RRMS) have poorer neurite density — a measure that relates to the amount of nerve cell projections, including axons and dendrites involved in nerve-to-nerve communication — in the brain and spinal cord than do those without this disease, a study shows. This measure, especially…

What worries you most about living with multiple sclerosis? I’m catching up with a small survey by Can Do MS, an organization that promotes health and wellness education programs. The survey results, released in September, show that disease progression, financial concerns, and loss of independence are at the…

Siemens Healthineers has signed a license and supply agreement with Quanterix that helps it in developing blood tests for neurofilament light chain (NfL) to aid in early disease detection, evidence of progression, and measuring treatment response in people with neurological disorders such as multiple sclerosis (MS). Siemens Healthineers…

A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including multiple sclerosis, so to better predict a patient’s likely response to treatment and likely disease progression. The project, called 3TR…

SARM1 inhibitors are a potential oral treatment to slow disease progression in neurodegenerative diseases like multiple sclerosis (MS), according to preclinical results that show the inhibitors protect nerve cells from damage in mice and cell cultures. Researchers at Disarm Therapeutics presented the findings in a poster titled “…

The levels of neurofilament light chain (NfL) and chitinase3-like1 (CHI3L1) in the cerebrospinal fluid — the liquid that surrounds the brain and spinal cord — serve as respective biomarkers of disease activity and progression in multiple sclerosis (MS), a study reports. Measuring levels of both proteins also helps to…

Receiving a diagnosis of multiple sclerosis (MS), a progressive neurological disorder, can be frightening. One of the first things patients ask is — what does this mean for me? Will my life expectancy drop with this diagnosis? What is life expectancy? Life expectancy is a “best guess” of…

Many treatments for multiple sclerosis (MS) are targeted at reducing inflammation, thereby slowing progression of the autoimmune disease. An anti-inflammatory diet also may slow disease progression, as well as enhance the positive effects of anti-inflammatory medications. In MS, the immune system mistakenly attacks the protein coat that surrounds nerve…

A genetic variant in the galanin gene (GAL) appears to be a risk factor for more severe multiple sclerosis (MS), nearly doubling the risk of rapidly progressive disease, particularly in patients whose disease onset occurs…

Through its Stop MS Appeal campaign, the United Kingdom’s MS Society seeks to raise £100 million (almost $125 million) within the next decade to advance research and treatments that will stop multiple sclerosis (MS) progression. Over the next three months, the organization will run an extensive advertising campaign…

The volume of atrophied (shrunken) regions in the brain, as visible through magnetic resonance imaging (MRI) scans, can predict disease progression in people with multiple sclerosis (MS), new research reveals. The finding was published in the journal Radiology in an article titled, “Atrophied Brain T2 Lesion Volume…

In this column, I take a look at more exciting research from the ECTRIMS2019 conference this month. #ECTRIMS2019 – Ozanimod’s ‘Key Advantages’ May Lead to New First-line MS Therapy: Interview with Neurologist Jeffrey Cohen This year we’ve seen the approval of two new multiple sclerosis treatments in the United…

Early and continuous treatment with Ocrevus (ocrelizumab) leads to a greater and more durable slowing of disability progression — seen for up to 6.5 years — in people with primary progressive multiple sclerosis (PPMS), according to long-term data on its use in PPMS patients in a Phase 3…

Age at disease onset is tightly linked to clinical outcomes in multiple sclerosis patients, a Swiss study in those on disease-modifying therapies (DMTs) reports. It found a risk of continuous relapses more likely in pediatric MS, and that of disease progression in those with adult-onset MS. Patients at age 40…

Patients with progressive multiple sclerosis (MS) have higher levels of protein markers of activated glial cells than those with relapsing-remitting MS (RRMS) or patients with other neurological disorders, according to a new study. The findings also indicated that scoring the extent of glial involvement in relation to nerve…

Mayzent (siponimod) reduces the risk of people with secondary progressive multiple sclerosis (SPMS) becoming dependent on a wheelchair, a new analysis of the EXPAND study shows. These findings further corroborate prior trial data demonstrating that Mayzent use delays disability progression and cognitive decline in SPMS patients. The results…

Oxcarbazepine, an anti-epileptic medicine, given in combination with a disease-modifying therapy (DMT) may help to stop disability progression in multiple sclerosis (MS) patients, results of Phase 2 trial suggest. Monica Marta, PhD, with Queen Mary University of London and Barts Health NHS Trust/The Royal London Hospital presented the data at the…

Transplanting mesenchymal stem cells (MSCs) is safe and can delay disease progression in people with active, progressive multiple sclerosis (MS), according to results from a single-center clinical trial conducted in Israel. Six months after the transplant, a considerable proportion of patients showed no signs of disease activity, compared to…

Multiple sclerosis (MS) experts discuss disease causes and current treatment options in a new video series released by the multimedia and peer-reviewed science journal, The American Journal of Managed Care (AJMC).  The free and online video series is part…

Monthly injections of ofatumumab led to more clinically meaningful reductions in relapse rates and delayed disability progression than did daily treatment with Aubagio (teriflunomide) tablets in people with relapsing forms of multiple sclerosis (MS), results from two Phase 3 trials showed. Ofatumumab, formerly known as OMB157, is a potent, self-administered…